REGN Regeneron Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: REGN

Price (delayed)

$764.89

Market cap

$78.75B

P/E Ratio

18.24

Dividend/share

$3.64

EPS

$41.94

Enterprise value

$79B

?
Relative Growth: Rel. Growth: 70
Relative Strength: Rel. Strength: 64
Relative Valuation: Rel. Valuation: 51
Relative Profitability: Rel. Profitability: 83

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine ...

Highlights
The revenue has increased by 9% YoY and by 4.1% QoQ
Regeneron Pharmaceuticals's gross profit has increased by 8% YoY and by 4.5% from the previous quarter
The quick ratio has contracted by 26% YoY and by 7% from the previous quarter
REGN's price to earnings (P/E) is 14% higher than its last 4 quarters average of 16.0 and 7% higher than its 5-year quarterly average of 17.0
Sector: Healthcare
Industry: Biotechnology
Website: http://www.regeneron.com
Peers: AMGN ALNY BIIB NVS

Key stats

What are the main financial stats of REGN

REGN stock price

How has the Regeneron Pharmaceuticals stock price performed over time
Intraday
0.3%
1 week
14.65%
1 month
16.91%
1 year
36.86%
YTD
-0.9%
QTD
22.67%

Financial performance

How have Regeneron Pharmaceuticals's revenue and profit performed over time
Revenue
$15.53B
Gross profit
$13.18B
Operating income
$3.84B
Net income
$4.33B
Gross margin
84.9%
Net margin
27.9%
The net margin has decreased by 11% YoY and by 6% from the previous quarter
The revenue has increased by 9% YoY and by 4.1% QoQ
Regeneron Pharmaceuticals's operating margin has decreased by 9% YoY
Regeneron Pharmaceuticals's gross profit has increased by 8% YoY and by 4.5% from the previous quarter

Price vs fundamentals

How does REGN's price correlate with its fundamentals

Growth

What is Regeneron Pharmaceuticals's growth rate over time

Valuation

What is Regeneron Pharmaceuticals stock price valuation
REGN P/E details
P/E
18.24
P/B
2.53
P/S
5.06
EV/EBIT
15.13
EV/EBITDA
13.74
EV/Sales
5.09
REGN's price to earnings (P/E) is 14% higher than its last 4 quarters average of 16.0 and 7% higher than its 5-year quarterly average of 17.0
REGN's price to book (P/B) is 21% less than its 5-year quarterly average of 3.2 but 10% more than its last 4 quarters average of 2.3
The equity has grown by 6% year-on-year
The P/S is 11% lower than the 5-year quarterly average of 5.7 but 5% higher than the last 4 quarters average of 4.8
The revenue has increased by 9% YoY and by 4.1% QoQ

Efficiency

How efficient is Regeneron Pharmaceuticals business performance
The return on assets has declined by 10% year-on-year and by 4.5% since the previous quarter
Regeneron Pharmaceuticals's return on equity has decreased by 9% YoY and by 3.5% QoQ
The company's return on sales fell by 3.7% QoQ and by 2.9% YoY
Regeneron Pharmaceuticals's return on invested capital has increased by 2% YoY

Dividends

What is REGN's dividend history
Dividend details
DPS
$3.64
Dividend yield
0.48%
Payout ratio
8.7%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Regeneron Pharmaceuticals financials performed over time
The current ratio is down by 27% YoY and by 6% QoQ
The quick ratio has contracted by 26% YoY and by 7% from the previous quarter
The debt is 91% less than the equity
The equity has grown by 6% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.